Attenuation of contractile responses to sympathetic co-transmitters in veins from subjects with essential hypertension

Clinical Autonomic Research

Volumn 7, Issue 2, 1997, Pages 69-76

  Lind, H ^a   Erlinge, D ^a   Brunkwall, J ^b   Edvinsson, L ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Essential hypertension; Neuropeptide Y; Noradrenaline; Vasoconstriction; , methylene ATP

Indexed keywords

ACETYLCHOLINE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; NEUROPEPTIDE Y; NORADRENALIN; POTASSIUM ION;

ADRENERGIC TRANSMISSION; ADULT; AGED; ARTERY CONSTRICTION; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN TISSUE; MALE; SKIN BLOOD VESSEL; VENOCONSTRICTION;

EID: 0030915401     PISSN: 09599851     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02267749     Document Type: Article

References (59)

1. Lundberg JM, Terenius L, Hökfelt T et al. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 1982; 116: 477-480.
2. Burnstock G. Overview: purinergic mechanisms. Ann N Y Acad Sci 1990; 603: 1-17.
3. Edvinsson L, Copeland JR, Emson PC, McCulloch J, Uddman R. Nerve fibers containing neuropeptide Y in the cerebrovascular bed: immunocytochemistry, radioimmunoassay and vasomotor effects. J Cereb Blood Flow Metab 1987; 7: 45-57.
4. Edvinsson L, Håkanson R, Wahlestedt C, Uddman R. Effects of neuropeptide Y on the cardiovascular system. Trends Pharmacol Sci 1987; 8: 231-235.
5. Lundberg JM, Torsell L, Sollevi A et al. Neuropeptide Y and sympathetic vascular control in man. Regul Pept 1985; 13: 41-52.
6. Solt VB, Brown MR, Kennedy B, Kolterman OG, Ziegler MG. Elevated insulin, norepinephrine and neuropeptide Y in hypertension. Am J Hypertens 1990; 3: 823-828.
7. Erlinge D, Ekman R, Thulin T, Edvinsson L. Neuropeptide Y-like immunoreactivity and hypertension. J Hypertens 1992; 10: 1221-1225.
8. Lind H, Brudin L, Castenfors J, Hedner T, Lindholm L, Edvinsson L. The effect of α-trinositol on haemodynamic variables and neuropeptide Y levels in a pilot study of hypertensives and healthy volunteers. Blood Pressure 1994; 3: 242-247.
9. Lemne CE, Lundeberg T, Theodorsson E, de Faire U. Increased basal concentrations of endothelin in borderline hypertension. J Hypertens 1994; 12: 1069-1074.
10. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept 1994; 50: 259-265.
11. Andersson D, Brunkwall J, Bergqvist D, Edvinsson L. Diminished contractile responses to neuropeptide Y of arteries from diabetic rabbits. J Autonom Nerv Syst 1992; 37: 215-222.
12. Lind H, Erlinge D, Brunkwall J, Edvinsson L. Selective attenuation of neuropeptide Y mediated contractile responses in blood vessels from patients with diabetes mellitus (NIDDM). Clin Autonom Res 1995; 5: 191-197.
13. Feranninni E, Buzzigoli G, Belladonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
14. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 2, overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
15. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035-2038.
16. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscular sympathetic nerve activity in essential hypertension. Hypertension 1989; 13: 870-877.
17. Andersson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertension in humans: evidence from direct intraneural recordings. Hypertension 1989; 14: 177-183.
18. Minson RB, McRitchie RJ, Morris MJ, Chalmers JP, Smith RM. Effects of neuropeptide Y on cardiac performance and renal blood flow in conscious normotensive and renal hypertensive rabbits. Clin Exp Hypertens 1990; 12: 267-284.
19. Thulesius O, Gjores JE, Berlin E. Vascular reactivity of normotensive and hypertensive human arteries. Gen Pharmacol 1983; 14: 153-154.
20. Lipe S, Moulds RFW. In vitro calcium dependence of arterial smooth muscle in human hypertension. Clin Exp Pharmacol Physiol 1985; 12: 319-323.
21. Högestedt ED, Andersson KE, Edvinsson L. Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels. Acta Physiol Scand 1983; 117: 449-461.
22. Nielsen H, Mortensen FV, Mulvany MJ. Responses to noradrenaline in human subcutaneous resistance arteries are mediated by both alpha 1- and alpha 2-adrenoceptors. Br J Pharmacol 1990; 99: 31-34.
23. 1 receptor antisense oligodeoxynucleotide specifically inhibits neuropeptide Y-evoked vasoconstriction. Eur J Pharmacol 1993; 240: 77-80.
24. Martin GN, Thom SA, Sever PS. The effects of adenosine triphosphate (ATP) and related purines on human isolated subcutaneous arteries and omental resistance arteries. Br J Pharmacol 1991; 102: 645-650.
25. Leppert J, Nilsson H, Myrdal U, Edvinsson L, Hedner T, Ringqvist I. Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls. Cardiovasc Drugs Ther 1993; 7: 901-907.
26. Angus JA, Lew MJ. Interpretation of the acetylcholine test of endothelial cell dysfunction in hypertension. J Hypertens 1992; 10 (Suppl. 7): 179-186.
27. Aalkjaer C, Heagerty AM, Swales JD, Thurston H. Endothelial-dependent relaxation in human subcutaneous resistance vessels. Blood Vess 1987; 24: 85-87.
28. Valdemarsson S, Edvinsson L, Ekman R, Hedner T, Sjöholm A. Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors. J Intern Med 1991; 230: 325-331.
29. Högestedt ED, Andersson KE. Mechanisms behind the biphasic contractile response to potassium depolarization in isolated rat cerebral arteries. J Pharmacol Exp Ther 1984; 228: 187-195.
30. Sjögren A, Edvinsson L. Vasomotor changes in isolated coronary arteries from diabetic rats. Acta Physiol Scand 1988; 134: 429-436.
31. Schiffrin EL, Deng LY, Larochelle P. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens 1992; 10: 437-444.
32. Schiffrin EL, Deng LY, Larochelle P. Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients. Clin Invest Med 1993; 16: 177-186.
33. 2 purinoceptors'. Trends Pharmacol Sci 1995; 17: 53-55.
34. Edvinsson L, Ekman R, Thulin T. Increased levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regul Pept 1991; 32: 279-287.
35. Goldstein DS, Lake CR, Chernow B et al. Age dependence of hypertensive-normotensive differences in plasma norepinephrine. Hypertension 1983; 5: 100-104.
36. Kjeldsen SE, Eide I, Aakesson I, Leren P. Increased arterial catecholamine concentrations in 50-year-old men with hypertension. Scand J Clin Lab Invest 1983; 43: 343-349.
37. Angus JA, Jennings GL, Sudhir K. Enhanced contraction to noradrenaline, serotonin and nerve stimulation but normal endothelium-derived relaxing factor response in skin small arteries in human primary hypertension. Clin Exp Pharmacol Physiol 1992; 19(Suppl. 19): 39-47.
38. Moulds RFW. Reduced responses to noradrenaline on isolated digital arteries from hypertensives. Clin Exp Pharmacol Physiol 1980; 7: 505-508.
39. Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mullany MJ. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 1987; 61: 181-186.
40. Vidal M, Hicks PE, Langer SZ. Differential effects of α-β-methylene ATP on responses to nerve stimulation in SHR and WKY tail arteries. Naunyn-Schmeidberg's Arch Pharmacol 1986; 332: 384-390.
41. Guild SB, Jenkinson S, Muir TC. The interaction between noradrenaline and ATP upon polyphospnoinositide metabolism and contraction in tail arteries from normo- and hypertensive rats. J Pharmacol Physiol 1992; 44: 836-840.
42. Danziel HH, Machaly M, Sneddon P. Comparison of the prurinergic contribution to sympathetic vascular responses in SHR and WKY rats in vitro and in vivo. Eur J Pharmacol 1989; 173: 19-26.
43. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Cardiol 1993; 21: 1145-1151.
44. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87: 1475-1481.
45. Panza JA, Casino PR, Badar DM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-1474.
46. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-933.
47. Taddei S, Mattei P, Virdis A, Sudano I, Ghiadoni L, Salvetti A. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 1994; 23: 485-490.
48. Treasure CB, Klein JL, Vita JA et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
49. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med 1994; 330: 1036-1040.
50. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
51. Lund-Johansen P. Haemodynamics in early essential hypertension. Acta Med Scand 1967; 181 (Suppl. 482): 1-101.
52. Safar ME, London GM, Levenson JA et al. Rapid dextran infusion in essential hypertension. Hypertension 1979; 1: 615-623.
53. Safar ME, London GM. Venous system in essential hypertension. Clin Sci 1985; 69: 497-504.
54. Safar ME, London GM. Arterial and venous compliance in sustained essential hypertension. Hypertension 1987; 10: 133-139.
55. Takeshita A, Imaizuma T, Ashihara T et al. Limited maximal vasodilator capacity of forearm resistance vessels in normotensive men with familiar predisposition to hypertension. Circ Res 1982; 50: 671-677.
56. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
57. Lindholm L, Eijlertsson G, Scherstén B. High risk of cerebro-cardiovascular morbidity in well controlled male hypertensives. Acta Med Scand 1984; 216: 251-256.
58. 1 receptor antagonist. Eur J Pharmacol 1994; 271: R11-R13.
59. Zee RY, Bennett CL, Schrader AP, Morris BJ. Frequencies of candidate genes in different age groups in hypertensives. Clin Exp Pharmacol Physiol 1994; 21: 925-930.